EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

In this segment, Dr. Sands asks Dr. Cooper to discuss the role of intracranial efficacy in guiding first-line treatment decisions for EGFR-mutated non-small cell lung cancer. Dr. Cooper emphasizes that central nervous system involvement is common in this patient population, making CNS activity a critical factor when selecting therapy. She highlights that treatments with strong intracranial penetration and durable CNS control are particularly important, especially for patients with existing or high risk of brain metastases. The discussion also addresses how CNS outcomes from clinical trials are interpreted alongside systemic efficacy data, including progression-free and overall survival. Dr. Cooper notes that preventing or delaying CNS progression can significantly impact patient quality of life and overall disease management. Overall, this segment underscores that CNS efficacy is a key consideration in treatment selection and plays a central role in individualized decision-making in EGFR-mutated NSCLC.